News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alexion Pharmaceuticals Inc. (ALXN) Release: European Commission (EC)Grants Orphan Drug Designation To Soliris® (Eculizumab) For Prevention Of Delayed Graft Function (DGF) After Solid Organ Transplantation



2/24/2014 8:11:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the European Commission has granted an orphan drug designation (ODD) to SolirisĀ® (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function (DGF) after solid organ transplantation. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation. In patients undergoing kidney transplantation, patients who develop DGF require dialysis in order to survive. 1-3

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES